Preprint · CC-BY
via OpenAlex
High-content screening identifies FDA-approved activators of mitophagy
Carlo Fiore Viscomi, Giacomo Giacchin, Valeria Balmaceda, Marta Giacomello, Andrea Eastes, Samantha Corrà, Lucía Fernández-del-Río, Nikole Scillitani, Davide Steffan, Marco Sandri, Erika Fernández‐Vizarra, Orian S. Shirihai, Cristiane Benincá
bioRxiv (Cold Spring Harbor Laboratory) · 2026
Abstract
Mitochondrial diseases are highly heterogeneous disorders caused by defects in oxidative phosphorylation, for which only limited therapeutic options are available. The elimination of dysfunctional mitochondria via mitophagy activation is an attractive strategy to treat several mitochondrial diseases, irrespective of the underlying genetic defect. To identify pharmacological activators of this pathway, we performed a high-content screening of 1,971 FDA-approved compounds using cellular reporters of TFEB nuclear translocation and mitophagy. This screening identified 294 compounds that promoted TFEB translocation, nine of which increased the number of mitolysosomes without compromising cell viability or damaging mitochondria. Among the selected compounds, Meptazinol and Ponatinib emerged as the top-ranked mitophagy inducers in fibroblasts from patients with complex I and IV deficiency, respectively, and were prioritised for further characterisation. However, they did not rescue the bioenergetic defect, suggesting that the stimulation of mitophagy per se is not sufficient to ameliorate the OXPHOS defect in mitochondrial diseases. Overall, our findings establish a scalable platform for the identification of pharmacological activators of TFEB and identify candidate compounds for therapeutic modulation of mitophagy.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.64898/2026.11.06.764995
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
Viscomi, C.F., Giacchin, G., Balmaceda, V., Giacomello, M., Eastes, A., Corrà, S., Fernández-del-Río, L., Scillitani, N., Steffan, D., Sandri, M., Fernández‐Vizarra, E., Shirihai, O.S., & Benincá, C. (2026). High-content screening identifies FDA-approved activators of mitophagy. <em>bioRxiv (Cold Spring Harbor Laboratory)</em>. https://doi.org/10.64898/2026.11.06.764995
Vancouver
Viscomi CF, Giacchin G, Balmaceda V, Giacomello M, Eastes A, Corrà S, et al. High-content screening identifies FDA-approved activators of mitophagy. bioRxiv (Cold Spring Harbor Laboratory). 2026. doi:10.64898/2026.11.06.764995.
BibTeX
@unpublished{carlo2026Highco,
title = {High-content screening identifies FDA-approved activators of mitophagy},
author = {Carlo Fiore Viscomi and Giacomo Giacchin and Valeria Balmaceda and Marta Giacomello and Andrea Eastes and Samantha Corrà and Lucía Fernández-del-Río and Nikole Scillitani and Davide Steffan and Marco Sandri and Erika Fernández‐Vizarra and Orian S. Shirihai and Cristiane Benincá},
journal = {bioRxiv (Cold Spring Harbor Laboratory)},
year = {2026},
doi = {10.64898/2026.11.06.764995},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Scientific Reports 2019
Open access · CC-BY
Pomegranate activates TFEB to promote autophagy-lysosomal fitness and mitophagy
Frontiers in Neuroscience 2018
Open access · CC-BY
Mitochondria and Calcium Regulation as Basis of Neurodegeneration Associated With Aging
Frontiers in Pharmacology 2025
Open access · CC-BY
Natural small molecules regulating the mitophagy pathway counteract the pathogenesis of diabetes and chronic complications
Fortune Journal of Health Sciences 2026
Open access · CC-BY
Mitochondria in the Crossfire: How Early-Life Interventions Shape Lifelong Health
Preprints.org 2019
Preprint · CC-BY
Iron Depletion Reduces Abce1 Transcripts While Inducing the Mitophagy Factors Pink1 and Parkin
Proceedings of the National Academy of Sciences 2025
Open access · CC-BY